ABSTRACT Introduction: Anti-angiogenic treatment with anti-vascular endothelial growth factor (anti-VEGF) for patients with exudative neovascular age-related macular degeneration (AMD) is the most effective in slowing the progression of visual loss and is first choice therapy. The safety data in patients with cerebrovascular accidents (CVA) in the last 6 months is limited since this condition has been considered as an exclusion criterion in...

Read More